Company intelligence / Profile preview

Nerisona

Ballerup, Denmark

Ownership: Private
Employees: ~4700
Development stage: Other

Overview

LEO Pharma is a global pharmaceutical company dedicated to advancing the standard of care in medical dermatology. Founded in 1908 and owned by the LEO Foundation, the company develops and manufactures therapies for patients with skin conditions such as psoriasis, eczema, and atopic dermatitis. LEO Pharma acquired the global skin health business of Bayer in 2018, which included the Nerisona brand of topical corticosteroids. The company's portfolio spans from established topical treatments to innovative biologics and systemic therapies, maintaining a presence in more than 130 countries.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Small moleculeMonoclonal antibodyBiologic
Industry: Pharma

Partnerships

BayerAstraZeneca

Beyond the preview

Go deeper on Nerisona.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nerisona.

Explore the full profile